ArticleCancers2022

Plasma Thymidine Kinase Activity as a Novel Biomarker in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibitors.

Fernanda Costa Svedman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.